WO1997006255A3 - Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods - Google Patents
Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods Download PDFInfo
- Publication number
- WO1997006255A3 WO1997006255A3 PCT/IB1996/001022 IB9601022W WO9706255A3 WO 1997006255 A3 WO1997006255 A3 WO 1997006255A3 IB 9601022 W IB9601022 W IB 9601022W WO 9706255 A3 WO9706255 A3 WO 9706255A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- primers
- probes
- detection methods
- protein gene
- gene family
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Abstract
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/011,356 US6656704B1 (en) | 1995-08-04 | 1996-08-05 | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
AT96931191T ATE310819T1 (en) | 1995-08-04 | 1996-08-05 | MAMMAL APOPTOSIS INHIBITOR PROTEIN GENE FAMILY, PRIMERS, SAMPLES AND METHODS OF DETECTION |
JP50827797A JP4458551B2 (en) | 1995-08-04 | 1996-08-05 | Mammalian apoptosis inhibitory protein gene family, primers, probes and detection methods |
DE69635482T DE69635482T2 (en) | 1995-08-04 | 1996-08-05 | MOWERING APOPTOSIS INHIBITOR PROTEIN GENE FAMILY, PRIMERS, SAMPLES AND PROCEDURE FOR PROOF |
EP96931191A EP0837939B1 (en) | 1995-08-04 | 1996-08-05 | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
CA002228635A CA2228635C (en) | 1995-08-04 | 1996-08-05 | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
US09/201,936 US6541457B2 (en) | 1995-08-04 | 1998-12-01 | Mammalian IAP gene family, primers, probes and detection methods |
US11/316,539 US20070009971A1 (en) | 1995-08-04 | 2005-12-22 | Mammalian IAP gene family, primers, probes, and detection methods |
US11/334,902 US20060205021A1 (en) | 1995-08-04 | 2006-01-19 | Mammalian IAP gene family, primers, probes and detection methods |
US11/492,111 US20070031903A1 (en) | 1995-08-04 | 2006-07-25 | Mammalian IAP gene family, primers, probes and detection methods |
US11/492,112 US20070031904A1 (en) | 1995-08-04 | 2006-07-25 | Mammalian IAP gene family, primers, probes and detection methods |
US11/492,113 US20070026470A1 (en) | 1995-08-04 | 2006-07-25 | Mammalian IAP gene family, primers, probes and detection methods |
US11/492,867 US20070027304A1 (en) | 1995-08-04 | 2006-07-26 | Mammalian IAP gene family, primers, probes and detection methods |
US11/492,868 US20070026494A1 (en) | 1995-08-04 | 2006-07-26 | Mammalian IAP gene family, primers, probes and detection methods |
US11/492,862 US20070048772A1 (en) | 1995-08-04 | 2006-07-26 | Mammalian IAP gene family, primers, probes and detection methods |
US11/498,244 US7776552B2 (en) | 1995-08-04 | 2006-08-03 | Mammalian IAP gene family, primers, probes and detection methods |
US11/498,897 US20070066524A1 (en) | 1995-08-04 | 2006-08-04 | Mammalian IAP gene family, primers, probes and detection methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/511,485 | 1995-08-04 | ||
US08/511,485 US5919912A (en) | 1995-08-04 | 1995-08-04 | Mammalian IAP antibodies and diagnostic kits |
US08/576,956 | 1995-12-22 | ||
US08/576,956 US6156535A (en) | 1995-08-04 | 1995-12-22 | Mammalian IAP gene family, primers, probes, and detection methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/576,956 Continuation-In-Part US6156535A (en) | 1995-08-04 | 1995-12-22 | Mammalian IAP gene family, primers, probes, and detection methods |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/011,356 A-371-Of-International US6656704B1 (en) | 1995-08-04 | 1996-08-05 | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
US09011356 A-371-Of-International | 1996-08-05 | ||
US09/201,936 Division US6541457B2 (en) | 1995-08-04 | 1998-12-01 | Mammalian IAP gene family, primers, probes and detection methods |
US09/201,932 Division US6689562B1 (en) | 1995-08-04 | 1998-12-01 | Mammalian IAP gene family, primers, probes and detection methods |
US10/600,272 Continuation US7067281B2 (en) | 1995-08-04 | 2003-06-20 | Mammalian IAP gene family, primers, probes and detection methods |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997006255A2 WO1997006255A2 (en) | 1997-02-20 |
WO1997006255A3 true WO1997006255A3 (en) | 1997-10-30 |
Family
ID=27057240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/001022 WO1997006255A2 (en) | 1995-08-04 | 1996-08-05 | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
Country Status (8)
Country | Link |
---|---|
US (17) | US6156535A (en) |
EP (2) | EP1757689A3 (en) |
JP (1) | JP4458551B2 (en) |
AT (1) | ATE310819T1 (en) |
CA (1) | CA2228635C (en) |
DE (1) | DE69635482T2 (en) |
ES (1) | ES2253756T3 (en) |
WO (1) | WO1997006255A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030073159A1 (en) * | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
US5958771A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US6156535A (en) * | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
AUPN727595A0 (en) * | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
GB9601108D0 (en) * | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US8043835B1 (en) | 1996-03-26 | 2011-10-25 | Oncomedx, Inc. | Methods for detecting and monitoring cancer using extracellular RNA |
ATE471150T1 (en) * | 1996-03-26 | 2010-07-15 | Kopreski Michael S | METHODS USING EXTRACELLURAER RNA EXTRACTED FROM PLASMA OR SERUM FOR DIAGNOSTIC MONITORING OR EVALUATION OF CANCER |
US7785842B2 (en) * | 1996-03-26 | 2010-08-31 | Oncomedx, Inc. | Comparative analysis of extracellular RNA species |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
DE69738776D1 (en) | 1996-04-26 | 2008-07-31 | Univ Ottawa | USE OF NAIP OR IAP FOR THE TREATMENT AND PREVENTION OF NEURAL DISEASES |
US6511828B1 (en) | 1996-05-31 | 2003-01-28 | Arch Development Corporation | Human and drosophila inhibitors of apoptosis proteins (IAPs) |
US5840535A (en) * | 1997-06-02 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | DNA encoding a zinc ring protein |
US6326481B1 (en) | 1998-06-02 | 2001-12-04 | Millennium Pharmaceuticals. Inc. | Molecules of the AIP-related protein family and uses thereof |
US6171821B1 (en) * | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
US20080261292A1 (en) * | 1998-09-22 | 2008-10-23 | Oncomedx, Inc. | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions |
CN1301769A (en) * | 1999-12-29 | 2001-07-04 | 复旦大学 | New polypeptide-human latexin protein 46 and polynucleotide coding such polypeptide |
ATE428116T1 (en) * | 2000-06-16 | 2009-04-15 | Rudel Thomas Dr | METHOD FOR IDENTIFYING MODIFIED PROTEINS DURING APOPTOSIS |
EP1164374A1 (en) * | 2000-06-16 | 2001-12-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying apoptosis-modified proteins |
US20020164576A1 (en) * | 2000-09-22 | 2002-11-07 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2 |
US20030044803A1 (en) * | 2000-09-22 | 2003-03-06 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US6901173B2 (en) * | 2001-04-25 | 2005-05-31 | Lockheed Martin Corporation | Scene-based non-uniformity correction for detector arrays |
US20070098728A1 (en) * | 2001-09-24 | 2007-05-03 | Pedersen Finn S | Novel compositions and methods in cancer |
US20100159464A1 (en) * | 2001-11-05 | 2010-06-24 | Oncomedx, Inc. | Method for Detection of DNA Methyltransferase RNA in Plasma and Serum |
US7820132B2 (en) * | 2001-12-14 | 2010-10-26 | Alliance For Sustainable Energy, Llc | Hot wire production of single-wall and multi-wall carbon nanotubes |
EP1539189A4 (en) * | 2002-03-25 | 2007-05-09 | Univ Boston | Method of using anti-apoptotic factors in gene expression |
CA2480308C (en) * | 2002-03-27 | 2011-10-04 | Aegera Therapeutics Inc. | Antisense iap nucleobase oligomers and uses thereof |
US20050233411A9 (en) * | 2003-02-07 | 2005-10-20 | Chunying Du | Compositions and methods for cleaving IAP |
WO2005017109A2 (en) * | 2003-06-30 | 2005-02-24 | Massachusetts Institute Of Technology | Nucleic acids and polypeptides required for cell survival in the absence of rb |
US8012944B2 (en) * | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
US7342093B2 (en) | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
EP1807157A2 (en) * | 2004-10-22 | 2007-07-18 | Neurologix, Inc. | Use of apoptosis inhibiting compounds in degenerative neurological disorders |
PT1889065E (en) | 2005-05-18 | 2013-09-27 | Novartis Ag | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
KR101506466B1 (en) | 2006-05-16 | 2015-03-27 | 파마사이언스 인크. | IAP BIR domain binding compounds |
WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
KR101215201B1 (en) | 2010-07-21 | 2012-12-26 | 단국대학교 산학협력단 | Composition for preventing or treating ischemic disease comprising X-chromosome linked inhibitor of apoptosis |
US20140127438A1 (en) | 2012-11-08 | 2014-05-08 | Robert L. Sherman, Jr. | Stabilized high-density polyethylene composition with improved resistance to deterioration and stabilizer system |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006814A1 (en) * | 1992-09-14 | 1994-03-31 | The General Hospital Corporation | Ikaros: a t cell pathway regulatory gene |
WO1995019431A1 (en) * | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665550A (en) * | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5594076A (en) * | 1991-09-24 | 1997-01-14 | The Pennsylvania Research Foundation | Hydrodegradable polyesters |
US6265157B1 (en) | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
US20030073159A1 (en) * | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
US6087173A (en) | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US5958771A (en) | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US5958772A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
WO1994023760A1 (en) * | 1993-04-14 | 1994-10-27 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5691179A (en) * | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
WO1995028497A1 (en) * | 1994-04-13 | 1995-10-26 | La Jolla Cancer Research Foundation | Interaction of proteins involved in a cell death pathway |
WO1995030435A2 (en) | 1994-05-10 | 1995-11-16 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
DE69534720D1 (en) * | 1994-10-18 | 2006-02-02 | Univ Ottawa | NEURONAL APOTOSIS INHIBITOR PROTEIN, GENE SEQUENCE AND MUTATIONS CAUSING SPINAL MUSCLE ATROPHY |
CA2203629A1 (en) | 1994-10-25 | 1996-05-02 | Dawn Smilek | Compositions and treatment for multiple sclerosis |
AU4695296A (en) | 1995-01-06 | 1996-07-24 | Immulogic Pharmaceutical Corporation | Compositions and methods for treating rheumatoid arthritis |
CA2220670A1 (en) | 1995-05-11 | 1996-11-14 | Peter L. Hudson | Human inhibitor of apoptosis gene 1 |
US5770690A (en) * | 1995-06-27 | 1998-06-23 | Neurex Corporation | Bax omega protein and methods |
US5877021A (en) | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US6156535A (en) * | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US5919912A (en) * | 1995-08-04 | 1999-07-06 | University Of Ottawa | Mammalian IAP antibodies and diagnostic kits |
AU6692996A (en) | 1995-08-08 | 1997-03-05 | Tularik Inc. | Inhibitors of apoptosis |
US6187557B1 (en) | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
US5834216A (en) * | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
AUPN727595A0 (en) * | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
US5605022A (en) * | 1995-12-26 | 1997-02-25 | Nci Building Systems, Inc. | Vented closure |
GB9601108D0 (en) * | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US6133437A (en) | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
WO1997049819A1 (en) * | 1996-06-24 | 1997-12-31 | Takara Shuzo Co., Ltd. | Novel amino-terminal deblocking enzyme |
WO1998022131A2 (en) | 1996-11-15 | 1998-05-28 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6228603B1 (en) | 1997-05-22 | 2001-05-08 | The Burnham Institute | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
CA2225187A1 (en) * | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
AU1080899A (en) | 1997-10-14 | 1999-05-03 | Nadine A. Tatton | Methods for increasing schwann cell survival |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6171821B1 (en) | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
CA2346773A1 (en) * | 1998-10-09 | 2000-04-20 | L. Sai Latha Shankar | Methods for treating multiple sclerosis |
US6187657B1 (en) * | 1999-03-24 | 2001-02-13 | Advanced Micro Devices, Inc. | Dual material gate MOSFET technique |
KR20000065690A (en) | 1999-04-08 | 2000-11-15 | 박종구 | Specific and stable antisense oligonucleotide, antisense DNA and process for preparation thereof |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US6395771B1 (en) | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20020119168A1 (en) * | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
KR100397275B1 (en) * | 2001-03-08 | 2003-09-17 | 주식회사 웰진 | Novel high-throughput system for functional genomics using unidirectional antisense cDNA library |
EP1572923A4 (en) | 2002-03-06 | 2007-10-31 | Rigel Pharmaceuticals Inc | Novel method for delivery and intracellular synthesis of sirna molecules |
CA2480308C (en) * | 2002-03-27 | 2011-10-04 | Aegera Therapeutics Inc. | Antisense iap nucleobase oligomers and uses thereof |
EP1469070A1 (en) | 2003-04-15 | 2004-10-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Livin-specific siRNAs for the treatment of therapy-resistant tumors |
CN101579529A (en) * | 2003-09-29 | 2009-11-18 | 托皮根药品公司 | Oligonucleotide compositions and method for treating disease including inflammatory conditions |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
US6946917B2 (en) * | 2003-11-25 | 2005-09-20 | Texas Instruments Incorporated | Generating an oscillating signal according to a control current |
-
1995
- 1995-12-22 US US08/576,956 patent/US6156535A/en not_active Expired - Lifetime
-
1996
- 1996-08-05 ES ES96931191T patent/ES2253756T3/en not_active Expired - Lifetime
- 1996-08-05 US US09/011,356 patent/US6656704B1/en not_active Expired - Lifetime
- 1996-08-05 JP JP50827797A patent/JP4458551B2/en not_active Expired - Fee Related
- 1996-08-05 EP EP05025419A patent/EP1757689A3/en not_active Withdrawn
- 1996-08-05 AT AT96931191T patent/ATE310819T1/en not_active IP Right Cessation
- 1996-08-05 WO PCT/IB1996/001022 patent/WO1997006255A2/en active IP Right Grant
- 1996-08-05 EP EP96931191A patent/EP0837939B1/en not_active Expired - Lifetime
- 1996-08-05 DE DE69635482T patent/DE69635482T2/en not_active Expired - Lifetime
- 1996-08-05 CA CA002228635A patent/CA2228635C/en not_active Expired - Fee Related
-
1998
- 1998-12-01 US US09/201,936 patent/US6541457B2/en not_active Expired - Fee Related
- 1998-12-01 US US09/201,932 patent/US6689562B1/en not_active Expired - Lifetime
-
2000
- 2000-09-01 US US09/654,743 patent/US6977158B1/en not_active Expired - Fee Related
-
2003
- 2003-06-20 US US10/600,272 patent/US7067281B2/en not_active Expired - Fee Related
-
2005
- 2005-09-01 US US11/217,557 patent/US20060127927A1/en not_active Abandoned
- 2005-12-22 US US11/316,539 patent/US20070009971A1/en not_active Abandoned
-
2006
- 2006-01-19 US US11/334,902 patent/US20060205021A1/en not_active Abandoned
- 2006-07-25 US US11/492,112 patent/US20070031904A1/en not_active Abandoned
- 2006-07-25 US US11/492,111 patent/US20070031903A1/en not_active Abandoned
- 2006-07-25 US US11/492,113 patent/US20070026470A1/en not_active Abandoned
- 2006-07-26 US US11/492,862 patent/US20070048772A1/en not_active Abandoned
- 2006-07-26 US US11/492,867 patent/US20070027304A1/en not_active Abandoned
- 2006-07-26 US US11/492,868 patent/US20070026494A1/en not_active Abandoned
- 2006-08-03 US US11/498,244 patent/US7776552B2/en not_active Expired - Fee Related
- 2006-08-04 US US11/498,897 patent/US20070066524A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006814A1 (en) * | 1992-09-14 | 1994-03-31 | The General Hospital Corporation | Ikaros: a t cell pathway regulatory gene |
WO1995019431A1 (en) * | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
Non-Patent Citations (7)
Title |
---|
CLEM RJ ET AL: "ANTI-APOPTOTIC GENES OF BACULOVIRUSES", CELL DEATH AND DIFFERENTIATION, 1996, 3, 9-16, XP000611842 * |
CLEM RJ ET AL: "Control of programmed cell death by the baculovirus genes p35 and iap.", MOL CELL BIOL, AUG 1994, 14 (8) P5212-22, UNITED STATES, XP000611843 * |
CROOK NE ET AL: "An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif.", J VIROL, APR 1993, 67 (4) P2168-74, UNITED STATES, XP000611841 * |
DUCKETT CS ET AL: "A CONSERVED FAMILY OF CELLULAR GENES RELATED TO THE BACULOVIRUS IAP GENE AND ENCODING APOPTOSIS INHIBITORS", EMBO JOURNAL, 1996, 15, 2685-2694, XP002032297 * |
LISTON P ET AL: "Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes.", NATURE, JAN 25 1996, 379 (6563) P349-53, ENGLAND, XP002032296 * |
ROTHE M ET AL: "The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins.", CELL, DEC 29 1995, 83 (7) P1243-52, UNITED STATES, XP002032302 * |
ROY N ET AL: "The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy [see comments]", CELL, JAN 13 1995, 80 (1) P167-78, UNITED STATES, XP002032295 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997006255A3 (en) | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods | |
Worland et al. | Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae | |
Brady et al. | A purification of adenosine deaminase from the superficial mucosa of calf intestine | |
WO2000027994A3 (en) | Chlamydia pneumoniae genome sequence | |
DE60043443D1 (en) | PHYTASE ENZYMES, CODUCTIVE NUCLEIC ACIDS, AND SUCH VECTORS AND HOST CELLS | |
HK1021648A1 (en) | Human plasma hyaluronidase | |
HUP0004611A2 (en) | April- a novel protein with growth effects | |
WO1997033996A3 (en) | Human bikunin | |
DK1005540T3 (en) | IKK-beta proteins, nucleic acids and methods | |
EP0701563A4 (en) | Gene transfer for treating a connective tissue of a mammalian host | |
WO1998007850A3 (en) | Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans | |
WO1999025878A3 (en) | Methods for modulating and identifying cellular senescence | |
Peterson et al. | A relationship between the yeast cell cycle genes CDC4 and CDC36 and the ets sequence of oncogenic virus E26 | |
Takeshita et al. | Mouse deoxyribonuclease I (DNase I): biochemical and immunological characterization, cDNA structure and tissue distribution | |
WO2001019966A3 (en) | Isolation of muscle-derived stem cells and uses therefor | |
WO2000009693A3 (en) | Identification of the gene causing the mouse scurfy phenotype and its human ortholog | |
WO1994000572A3 (en) | Gene for ataxia-telangiectasia complementation group d (atdc) | |
WO1997014797A3 (en) | Cystatin m, a novel cysteine proteinase inhibitor | |
WO2002014361A3 (en) | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER | |
Fujiwara et al. | cDNA cloning of p42, a shared subunit of two proteasome regulatory proteins, reveals a novel member of the AAA protein family | |
SE9900615L (en) | Method and kit for early prediction of cancer | |
CA2403947A1 (en) | Bir domains of mammalian iap gene family | |
WO2003066808A3 (en) | Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells | |
AU1887888A (en) | Human papillomavirus type 41, its DNA and the proteins encoded therefrom | |
EP0778347A3 (en) | ATP and nucleic acid-binding protein with putative helicase and ATPase characteristics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2228635 Country of ref document: CA Ref country code: CA Ref document number: 2228635 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1997 508277 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996931191 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996931191 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09011356 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996931191 Country of ref document: EP |